Answers are grounded in this paper and cite their sources.
With the intensification of population aging, the demand for lumbar spinal fusion among osteoporotic patients has increased significantly; however, postoperative fusion failure resulting from abnormal bone metabolism remains a prominent concern. Building upon advances in surgical techniques, pharmacological therapy has gained increasing attention as a critical strategy for regulating bone metabolism and improving lumbar fusion rates. This review summarizes the effects of anti-osteoporosis drugs on lumbar fusion rates. Bone anabolic agents, such as teriparatide, can effectively enhance fusion rates. Anti-resorptive agents, including bisphosphonates, maintain bone mineral density without compromising overall fusion outcomes. Vitamins D and K exert adjunctive effects by regulating bone metabolic balance, whereas the clinical utility of calcitonin and selective estrogen receptor modulators (SERMs) remains to be supported by additional evidence. Romosozumab currently lacks robust clinical evidence regarding human spinal fusion rates. Combination regimens, such as alendronate combined with curcumin, or teriparatide combined with bisphosphonates or denosumab, may optimize bone healing through synergistic mechanisms; however, their safety and efficacy require validation through large-scale clinical studies.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: